Pipeline
The lead program in acute GvHD is funded through the EIC Accelerator and targets Phase 2b on a conditional approval pathway. Around it, a staged set of expansion programs extends selective Treg activation into dermatology, rheumatology and lung disease.
Development status
Six programs, one mechanism: selective activation of regulatory T cells.
Transplanted donor immune cells attack the recipient's skin, liver, and GI tract — potentially life-threatening. U.S. Orphan Drug Designation granted.
Chronic autoimmune inflammation of the oral mucosa causing painful ulcerations.
~30–40% of RA patients on adalimumab lose response within ~12–18 months; ~15–25% of bDMARD failures are refractory to any later-line treatment.
Autoimmune skin condition causing white, thinning anogenital patches with pain or scarring.
Allergic lung reaction to Aspergillus fungi causing airway inflammation.
Chronic lung condition from long-term inflammation that damages lung tissue.
Program status as presented by CD4 Therapeutics, July 2026. Bars indicate the phase reached or targeted per program, not elapsed time.
Structure
60% of stem cell transplant patients develop acute GvHD; more than half fail first-line steroids. Phase 2b on a conditional approval pathway, with U.S. Orphan Drug Designation and the graft-versus-leukemia effect preserved.
Target: Phase 2b
oLP: chronic, pre-malignant inflammation with no approved therapy, 3M+ patients worldwide. RA: clinical proof-of-concept already achieved with Tregalizumab.
Phase 2b target and pilot Phase 2
Scale-up programs extending selective Treg activation into further immune-driven skin and lung disease.
Entering Phase 2b and targeting Phase 1
